amxt-1501
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 28, 2023 (NCT05717153)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Mammalian polyamine transporterINHIBITOR
Mammalian polyamine transporter inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCCCCCCCCCCCCCCC(=O)NCCCC[C@@H](N)C(=O)NCCCNCCCCNCCCN- Mol. weight
- 568.94 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068506 ↗
- ChEMBLCHEMBL474635 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07287917 | Phase 1/Phase 2 (Phase 2) | Dec 18, 2025 | Aminex Therapeutics, Inc. |
| NCT06465199 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2024 | Aminex Therapeutics, Inc., Pennsylvania State University |
| NCT05717153 | Early Phase 1 (Phase 1) | Aug 28, 2023 | Mayo Clinic, National Cancer Institute (NCI) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aminex Therapeutics, Inc. | For profit | 2 | 1 | 1 | 2024 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2023 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2023 |
| Pennsylvania State University | Academic/Hospital | 1 | 1 | 1 | 2024 |
4 organizations
Page 1 / 1